Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of EBI-031 for uveitis

Next Previous
Trial Profile

A phase I trial of EBI-031 for uveitis

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EBI 031 (Primary)
  • Indications Uveitis
  • Focus Adverse reactions

Most Recent Events

  • 07 Mar 2023 According to a Carisma Therapeutics media release, Carisma Therapeutics merged with the Sesen Bio. The combined companies are named as Carisma Therapeutics.
  • 16 May 2018 According to a Sesen Bio media release, Eleven Biotherapeutics changed its name to Sesen Bio.
  • 07 Jul 2016 According to an Eleven Biotherapeutics media release, the company's Investigational New Drug (IND) application for EBI-031 for treatment of ocular diseases, has become effective.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top